IMMX Stock Summary and Trading Ideas (Immix Biopharma | NASDAQ:IMMX)

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Immix Biopharma trades on the NASDAQ stock market under the symbol IMMX.

As of June 8, 2026, IMMX stock price declined to $7.87 with 1,016,841 million shares trading.

IMMX has a beta of 0.70, meaning it tends to be less sensitive to market movements. IMMX has a correlation of 0.01 to the broad based SPY ETF.

IMMX has a market cap of $560.26 million. This is considered a Small Cap stock.

In the last 3 years, IMMX traded as high as $11.61 and as low as $1.26.

The top ETF exchange traded funds that IMMX belongs to (by Net Assets): VTI, VXF, IWC, AVSC.

IMMX has outperformed the market in the last year with a return of +259.4%, while the SPY ETF gained +25.9%. However, in the most recent history, IMMX shares have underperformed the stock market with its stock returning -7.8% in the last 3 month period and -10.4% for the last 2 week period, while SPY has returned +8.8% and -0.9%, respectively.

IMMX support price is $7.46 and resistance is $8.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMMX shares will trade within this expected range on the day.